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Introduction
The synovium lines the noncartilaginous surfaces of the
diarthrodial joints, and synovial tissue is also found in
tendon sheaths and bursae [1]. Several rheumatic diseases
are characterized by synovial inflammation. In these con-
ditions, descriptive studies of synovial biopsy specimens
may contribute to an understanding of the events that
take place in vivo, and they complement experimental
animal studies as well as in-vitro studies. Examination of
synovial tissue is generally more relevant than synovial
fluid analysis, except, for example, the analysis of neu-
trophils and platelets, and studies of soluble mediators.
Recently, there has been an enormous upsurge in investi-
gations of the pathological changes in the synovium [2]
because of the availability of new methods to obtain
synovial biopsy samples [3,4] and because of the develop-
ment of immunohistological methods, in-situ hybridiza-
tion, and the polymerase chain reaction. Moreover, the
complementary DNA microarray technology may hold
great promise for synovial tissue analysis in the future [5].
Methods to obtain and evaluate synovial
biopsy samples
Synovial tissue may be obtained either at surgery, by blind
needle biopsy, or at arthroscopy. It is likely that tissue
obtained at joint replacement differs from that obtained
by blind-needle biopsy or arthroscopy because of clear dif-
ferences in patient selection. Obviously, surgery is inap-
propriate for studies on early rheumatoid arthritis (RA) or
for serial investigations. The blind-needle biopsy tech-
nique is safe, well tolerated and is technically easy to
perform. A limitation of this method is that its use in clini-
cal practice is often restricted to the suprapatellar pouch of
the knee joint. In addition, it is more difficult to obtain
sufficient tissue from clinically uninvolved joints, for
example after successful treatment. Arthroscopic sampling
of synovial tissue under direct vision is a similarly safe and
well tolerated procedure, but is more complicated and
expensive [3,6,7]. Most measures of inflammation in
needle biopsies are similar to those selected at arthroscopy
[4]. An advantage of arthroscopy is that it is always possi-
ble to obtain tissue in adequate amounts, even in clinically
quiescent joints. Moreover, arthroscopy allows access to
most joints and to most regions within the joint, including
the pannus–cartilage junction.
There is large variability of synovial inflammation
between individuals, different joints, and even within
joints [2]. The degree of morphologic heterogeneity in
synovial tissue samples obtained from a single joint could
suggest that evaluation of synovial tissue is unreliable
because of unavoidable sampling error. Several studies
[8–10], however, have shown that, despite the degree of
histologic variation, representative measures of several
parameters of synovial inflammation may be obtained by
examining a limited number of samples. For example,
quantification of T-cell infiltration and activation in sec-
tions derived from at least six different biopsy specimens
results in variance of less than 10% [10]. It is generally not
necessary to know the macroscopic appearance of the
rheumatoid synovium in order to obtain representative
samples [4,8].
There are essentially three methods to quantify the fea-
tures of synovial inflammation in biopsy samples: semi-
quantitative analysis, quantitative analysis and
computer-assisted analysis [11–13]. All three methods are
reliable in experienced hands. It can be anticipated that
digital image analysis will be increasingly important with
the use of more advanced computer systems.Arthritis Research    Vol 1 No 1 Tak and Breedveld
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Clinical studies
Histological features of the synovium have been docu-
mented in various clinical studies, describing associations
with disease activity [14,15] and prognosis [16,17]. These
studies underscore the important role of macrophages and
macrophage-derived mediators of inflammation and
destruction in RA. In addition, systematic comparison of
synovial tissue from RA patients in different phases of the
disease made it possible to define the cell infiltrate
[14,15,18–20], as well as the expression of adhesion mole-
cules [21], cytokines [14,22,23] and degrading enzymes
[17,20,24] in early disease. A major conclusion from this
work is that so-called early RA is already a chronic disease.
This may explain the observation that a notable percent-
age of RA patients have signs of joint destruction at the
time of initial diagnosis [25]. Preliminary work [26] has
identified some immunohistological features that are char-
acteristic for rheumatoid synovial tissue. More extensive
future studies may provide helpful markers, which could
be used for routine clinical practice.
Studies of synovial tissue may also play an important role
in the development of rational therapies in which biotech-
nology products are used to influence defined patho-
genetic mechanisms [27]. The design of optimal treatment
regimens for interventions with agents such as monoclonal
antibodies, soluble receptors, cytokines and peptides can
be facilitated by information regarding the actual achieve-
ment of the biological effect at the site of inflammation.
Such studies will also provide insight into the mode of
action of such agents. Additionally, analysis of serial biopsy
samples during treatment may provide useful alternative
end points for both joint inflammation and joint destruc-
tion. This approach could lead to a rapid screening method
that would require relatively low numbers of patients to
predict the effects of novel antirheumatic strategies.
Studies of the relation between a defined modification of
inflammation and the clinical course could also produce
information about the pathogenesis of rheumatic diseases.
Inflammatory cells in the synovium
The synovium comprises the intimal lining layer and the
synovial sublining [1]. The intimal lining layer consists
mainly of intimal macrophages and fibroblast-like synovio-
cytes. The synovium becomes hypertrophic and edematous
in various arthritides. Angioneogenesis, recruitment of
inflammatory cells under influence of chemokines, local
retention and cell proliferation all contribute to the accumu-
lation of cells in the inflamed synovium. The following dis-
cussion focuses on the major infiltrating cell populations.
Rheumatoid synovial tissue is characterized by marked
intimal lining hyperplasia and by accumulation of T cells,
plasma cells, macrophages, B cells, mast cells, natural
killer cells and dendritic cells in the synovial sublining
(Table 1, Fig. 1) [14,23,28–30]. Distinct patterns of
lymphoid organization can occur in the synovium; diffuse,
follicular and granulomatous variants have been distin-
guished [31]. In contrast to general belief, proliferation of
synovial tissue is mainly due to changes in the synovial
Figure 1
Rheumatoid synovial tissue showing (a) CD55+ fibroblast-like
synoviocytes in the intimal lining layer; (b) CD68+ macrophages in the
intimal lining layer and in the synovial sublining; and (c) CD3+ T cells in
lymphocyte aggregates and in the diffuse leucocyte infiltrate in the
synovial sublining. Original magnification ×100.
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sublining (Fig. 1). Important contributors are angioneoge-
nesis, oedema, massive cell infiltration and fibrosis. The
differences with other forms of arthritis are only gradual.
There is, for example, on average stronger infiltration by
macrophages, plasma cells and granzyme-positive cyto-
toxic cells in RA [23,26,30]. So-called pannocytes have
been observed at the pannus–cartilage junction [32,33].
These cells exhibit phenotypic and functional features of
both fibroblast-like synoviocytes and chondrocytes. Fur-
thermore, cells with features of osteoclasts have been
identified at the junction [34]; they are probably derived
from the monocyte/macrophage lineage.
Pathogenetic mechanisms in rheumatoid
arthritis
Although the aetiology of RA remains elusive, immune-
mediated mechanisms are probably of crucial importance.
The evidence to support a role of CD4+ T cells in the
immune response in RA patients [35,36] is substantial, but
circumstantial. A subset of the CD4+ cells in the syn-
ovium shows phenotypic evidence of prior activation, but
many of the T cells are small and few of them express
activation molecules such as transferrin and the inter-
leukin-2 receptor [22,37,38]. Of interest is that the per-
centage of interferon-g producing T cells [22,39] and the
detectable levels of T cell receptor-z protein [40,41] are
significantly lower in RA synovium than in a chronic T-
cell-mediated immunological reaction, such as tonsillitis or
tuberculous pleuritis. These data indicate that T cells in
RA synovium are in a peculiar activation state.
Lymphocyte aggregates (Fig. 1c) are observed in 50–60% of
RA patients, and can be surrounded by coronas of plasma
cells [14]. In these areas interdigitating dendritic cells are
observed in proximity to CD4+ T-cells [42–45]. Human
leucocyte antigen class II molecules and the costimulatory
molecule CD86 (B7-2), which has an important role in
antigen presentation, are expressed on these cells [46–48],
suggesting that interdigitating dendritic cells could present
antigen to CD4+ T cells. Whether this involves mainly
endogenous autoantigens [49,50] or exogenous agents, such
as bacteria [51] and viruses [52], remains to be elucidated.
Recent studies [51,53,54] have shown that there is a much
higher load of bacterial DNA and peptidoglycans in the
synovium than previously expected. Conceivably, the T-
cell response is directed at an array of different antigens,
which might well be a secondary phenomenon.
When the perivascular lymphocyte aggregates are large,
substantial numbers of B cells can be found in close associ-
ation with CD4+ cells and follicular dendritic cells [14,28].
Of importance is that fibroblast-like synoviocytes also have
intrinsic properties of follicular dendritic cells [55]. The
aggregates that consist mainly of CD4+ T cells and B cells
resemble germinal centers, although they are morphologi-
cally not identical to the germinal centers in lymphatic
organs [45,56]. The microenvironment suggests a close
functional relationship between follicular dendritic cells
and B cells in RA synovium, allowing activation and matu-
ration of the humoral immune response.
It has become clear that cells other than lymphocytes, in
particular activated macrophages (Fig. 1b) and fibroblast-
like synoviocytes (Fig. 1a), play a critical role as effector
cells in chronic disease [14,37,57,58]. Both cell types are
highly activated and secrete a variety of cytokines [59,60],
as well as matrix metalloproteinases [61,62]. Fibroblast-
like synoviocytes can also produce other factors, such as
proteoglycans and arachidonic acid metabolites [58,63].
The increase in the numbers of fibroblast-like synovio-
cytes can be explained in part by proliferation and by
impaired apoptosis. Although proliferation probably con-
tributes to some extent [64,65], inhibition of apoptosis in
particular provides an important explanation for the
increased cellularity [66]. Very few apoptotic cells are
found in the synovium of RA patients [67,68], despite the
presence of fragmented DNA in the intimal lining layer
[67,69]. Various mechanisms may be involved in causing
inadequate apoptosis: the development of mutations of
the p53 suppressor gene [70–72]; deficient functional Fas
ligand expression [73], overexpression of antiapoptotic
molecules, such as sentrin [74]; and activation of nuclear
factor-kB [75–77]. The marked increase in the expression
of granzymes A and B in RA patients [30,78,79] could be a
reactive attempt to induce apoptosis in synovial cells.
Interestingly, fibroblast-like synoviocytes from RA
patients exhibit many features of transformed cells
[58,72]. The presence of these ‘transformed’ cells in the
synovium may contribute to the autonomous progression
of pannus and joint destruction in a subset of RA patients.
Two-thirds or more of the cells in the hyperplastic intimal
lining layer in RA are macrophages, where they are partic-
ularly observed in the more superficial parts [80]. It is
generally believed that they originate from bone marrow-
derived monocytes that have migrated in response to
chemotactic factors [81]. Relatively little is known about
the factors that influence the specific retention of
macrophages in the intimal lining layer. It has recently
been suggested that the ligand pair CD55–CD97 could be
involved [82]. Fibroblast-like synoviocytes can be distin-
guished from other fibroblasts by the marked expression
of CD55 or complement decay accelerating factor. CD55
can act as a cellular ligand for the sevenspan-transmem-
brane molecule CD97, which is expressed by nearly all
intimal macrophages [82]. The microarchitecture of the
intimal lining layer strongly suggests that intimal
macrophages and fibroblast-like synoviocytes may specifi-
cally interact via this ligand pair. Of note is that intimal
macrophages exhibit stronger expression of CD97 than
macrophages in the synovial sublining, illustrating the
highly activated phenotype of the intimal macrophages inrheumatoid synovial tissue. The exact role of the
CD55–CD97 interaction in the pathogenesis of RA
remains to be elucidated.
The macrophages often also constitute the majority of the
inflammatory cells in the synovial sublining [14].
Macrophage infiltration occurs preferentially in areas adja-
cent to the articular cartilage [4]. Of interest is that most
cells in areas where synovial cells display tumour-like
morphology are macrophages [83]. The preferential accu-
mulation of macrophages at the pannus–cartilage junction
is probably related to the expression of a range of adhesion
molecules by macrophages [84–86] and to the effects of
selective chemotactic factors [87–89].
The importance of these cells and their soluble mediators is
supported by clinical observations. Local disease activity is
particularly associated with the number of macrophages and
the expression of cytokines, such as tumour necrosis factor
(TNF)-a and interleukin-6, in synovial tissue [14,15].
There is also a significant positive correlation between
intimal lining layer depth and cell counts for macrophages
in the synovial sublining on the one hand, and radiographic
signs of joint destruction after follow up on the other [16].
The pivotal role of TNF-a, at least in the majority of RA
patients, has been confirmed by the impressive effects of
specific therapeutic strategies targeting the TNF-a mole-
cule [90–92]. The importance of cytokines, which are
mainly derived from macrophages, is also illustrated by the
effects of treatment aimed at blocking the effects of inter-
leukin-1 [93,94] and interleukin-6 [95].
These observations have stimulated studies of the factors
that drive the production of proinflammatory cytokines,
such as TNF-a. It has been suggested [96] that cytokine-
stimulated T cells may contribute to the excessive produc-
tion of TNF-a in synovial tissue. Among the cytokines that
can promote a Th1-like proinflammatory response in the
synovium are interleukin-12 [97,98] and probably also IL-
18 [99]. Interleukin-15 is another cytokine that has drawn a
lot of attention as a potential factor implicated in the inter-
action between T cells and TNF-a-producing macrophages
[100–102]. In addition to cytokines, cell-surface molecules
may also play a role in driving the production of proinflam-
matory cytokines and matrix metalloproteinases by
macrophages and fibroblast-like synoviocytes [103,104].
Conclusion
There has been increased interest in the pathological
changes at the site of inflammation in patients with
various forms of arthritis. Several studies have focused on
methodological matters concerning synovial biopsy proce-
dures, sampling error and the methods used to quantify
synovial inflammation. This has led to the first steps in
the development of quality control systems and the stan-
dardization of methodology.
Preliminary studies have identified features of synovial
tissue that are associated with specific arthritides. More
extensive studies could yield important information for
differential diagnosis and estimating prognosis. Moreover,
studies on serial biopsy samples after experimental
therapy may help to understand the mechanism of action
of specific interventions. Such studies may also provide
insight into the role of specific cells and molecules in the
pathogenesis. Based on these and other investigations,
macrophages and fibroblast-like synoviocytes have been
recognized as key players in the effector phase of rheuma-
toid arthritis.
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